Introduction Adipose Derived Stem Cells (ADSCs)
ASCs have a self-renewal mechanism that accounts for their longevity. Cell based therapies that combine biomaterials, SCs and bioactive agents have identified the benefit that a constant source of autologous SCs with multipotential can offer [4] . Despite almost 30 years of extensive research on bone marrow stem cells (BMSCs) for potential use in regenerative medicine, low cell number, pain and morbidity upon cell harvest still hamper their effective use. Alternate sources of SCs including ADSCs, derived from the mesenchyme and easy to isolate from the supportive stroma have been shown to be harvested, multiplied and have multpotential and proliferative capacity comparable to BMSCs with significant less trauma and morbidity to donors. The multipotent differentiation capacity of ADSCs has been confirmed by differentiating into bone, cartilage, fat, heart, nerve, liver and smooth muscle [5] [6] [7] [8] . In addition, ADSCs have also been shown to be available in greater abundance, with less pain or morbidity to donors and with a greater potential to reduce an immune response in applications where autologous grafts have been implicated.
Cancer Stem Cells (CSCs)
Normal ASCs undergo an initial genetic mutation to become founder cells of solid tumours allowing these tumours to contain a sub-population of self-renewing and expanding SCs known as CSCs. It has even become evident that cancer can originate from normal SCs in a variety of different cancers and since cancer progression is an evolutionary process that generates multiple clones with a fresh identity, eradication of cancer can be futile if only one type of SC is targeted [9] . Postulated to regenerate tumour post-treatment, CSCs have been the basis of controversy for several years.
Having been shown to initiate tumorogenesis, CSCs have provided a novel model of cancer biology that holds great promise for future therapeutic developments [10] . Cellular heterogeneity of cancer cells have been appreciated for decades and yet the idea of developing more efficient and sensitive treatment regimes based on the concept of treatment-resistant CSCs was met with extreme enthusiasm with the identification of the first CSCs in 1977 [11] . During cell division CSCs, like normal SCs, can either generate more differentiated daughter cells or undergo self-renewal demonstrating the significance of the cellular pathways governing selfrenewal [10] . Therapeutic intervention should target key signalling pathways that are active in CSC self-renewal. These pathways include the WNT pathway (important for self-renewal and maintenance of SCs); the Notch pathway (overactivated expression of receptors and ligands leading to transformation) and the Hedgehog pathway (maintenance of SCs).
Low Intensity Laser Irradiation (LILI)
LILI, (especially red and near infrared light), has been shown to increase viability, protein expression and migration of SCs in vitro, and to stimulate proliferation of various types of cells mainly through the activation of mitochondrial respiratory chain and the initiation of cellular signaling [12, 13] . In addition, LILI has been shown to illicit different responses in different cell types depending on the intensity of irradiation. Molecular and cellular processes are inhibited or stimulated at different intensities of LILI as indicated by changes in metabolism, increased adenosine triphosphate (ATP) production and increased cellular migration [14] . Furthermore, LILI has also been shown to promote the proliferation of rat mesenchymal bone marrow, cardiac and ADSCs in vitro [14, 15] . It was recently demonstrated that not only do ADSCs respond well to external stimuli, including LILI, as a mechanism of inducing increased viability and proliferation, but differentiation into other cell lineages can be achieved with minimal invasive techniques such as careful selection and addition of growth factor combinations. Even in the absence of growth factors, the use of laser irradiation to stimulate differentiation has been shown in Normal Human Neural Progenitor Cells (NHNPCs) in vitro where NHNPCs are not only capable of being sustained by light in the absence of growth factors, but they are also able to differentiate normally as assessed by neurite formation [16] . Our work has focused on the ability of laser irradiation to increase proliferation of ADSCs, maintain their SC character and increase the rate and maintenance of differentiation of ADSCs into smooth muscle cells [17] .
De Villiers and co-workers indicated that LILI at 636 nm and 5 J/cm 2 do not induce differentiation of ADSCs into adipocytes over a 72 hour period despite inducing increased ADSC viability and proliferation [17] . In addition, the effect of different irradiation wavelengths and fluences on ADSC viability and proliferation has been investigated and it was shown that there is an indirect correlation between effect of LILI at different wavelengths and fluences and viability and proliferation of ADSCs. Higher wavelength and fluence (830 nm and 15 J/cm 2 ) inhibits viability and proliferation while red light (636 nm) and lower fluence (5 J/cm 2 ) shows promise as a use to stimulate propagation of low numbers of SCs in vitro [18] . Adding specific growth factors could enhance the differentiation of ADSCs into different cell types that could, in turn, be used in tissue engineering applications and reconstructive surgery. However, in order for this approach to be effective for use in tissue engineering certain criteria need to be met. These criteria include that the cells of interest should be found in abundance, should be harvested by a minimally invasive procedure and should have the capacity to differentiate into multiple cell lineages in vitro before being transplanted safely and effectively back into a host [19] .
Problems associated with Cancer Stem Cell Therapy
Most therapies for cancer involve the induction of cell death by causing damage to DNA. Normal SCs, also vulnerable to toxic cancer agents, have however developed several protective mechanisms against genotoxic stress. Evidence suggests that CSCs are relatively resistant to cytotoxic chemotherapeutics. Mechanisms whereby CSCs may be able to resist chemo-or radiotherapy-induced cell death may involve cell cycle kinetics. Rapidly dividing cells are more sensitive to cytotoxic therapies than quiescent cells. Additionally, CSCs are able to express drug resistant transporters found in hypoxic niches and enhanced by DNA repair capacity as well as the expression of specific drug detoxifying enzymes [20] . Therapeutics that cause minimal toxicity to normal cells while activating survival or self-renewal of CSCs is optimal. Monoclonal antibodybased therapy targeting the most useful CSC marker CD44 seems to have potential had it not been that CSC surface antigens may also be over-expressed by normal SCs. Targeting CSC-specific pathways to inactivate or kill CSCs would require extensive knowledge of both normal SC and CSC pathways prior to effective treatment modalities. To overcome the predicament of inducing cell death in normal SCs when targeting CSCs as a result of a lack of significant differences in targets between the two cell types, less toxic and invasive mechanisms of therapy may be preferential.
Genetic changes in CSC subclones leading to treatment resistance have introduced the option of multimodality approaches where conventional cytotoxic agents and CSC-specific therapies may overcome the genomic instability of CSCs. Cytotoxic therapy can shrink tumours but may spare some CSCs allowing the tumour to regrow while CSC-targeted therapy could remove the self-renewing tumour cells ( Figure 1A,  1 and 2 ). Fluorescent activated cell sorting facilitates CSC specific therapy by identification of CSCs prior to treatment ( Figure 1A, 3 and 4) . Genomic instability may result in CSC subclones rendering them resistant to a CSC specific therapy. Multi-modality treatment that combines cytotoxic treatment with CSC specific therapy may thus be more effective. Tumour re-growth would be unsustainable if it were possible to induce the differentiation of CSCs into active cancer cells prior to exposing to multimodality treatment regimes.
Reducing the expression of CSC inducer molecules including CD133 + in glioblastomas, or exposing breast cancer cells to retinoic acid inducing differentiation of CSCs, is but two different approaches in CSC therapy that have been investigated [9] . Inducing selective differentiation of CSCs into the active cancer cell using non-invasive and non-toxic methods such as LILI prior to cytotoxic or CSC specific therapy introduces a novel therapeutic alternative with potential and worthy of further investigation ( Figure 1B, 1 and 2 ). This would contribute to reducing the risk of post-treatment tumour regrowth and regeneration.
Conclusions
ADSCs and BMSCs have comparable immuneregulatory properties such as inhibition of the proliferation and cytokine secretion of human primary T cells in response to mitogens and allogenic T cells (1, 2) ; alternatively fluorescent identification of different cell types followed by CSC targeted therapy or finally cytotoxic CSC specific therapy (3, 4) . These therapies are all currently theoretical and require extensive knowledge of SC pathways and genomic instability to prevent resistance. (B) Inducing selective differentiation of CSCs into the tissue type of origin (active cancer cells) using non-invasive and non-toxic methods such as LILI prior to (A) introduces a novel therapeutic alternative (1, 2) .
increasing their potential for use in stem cell therapy with reduced transplantation rejection. ADSCs are, however, more easily accessible and available as well as having significant potential to proliferate and differentiate in culture [4] . The CSC theory has focussed attention of researchers on using models of malignancy which include tumours characterized by heterogenous cell populations. Cancer cell lines traditionally used in cancer research are monomorphic, mutated cells which often fail to represent primary cancer cells well. Tumour regrowth is a potential risk when using CSC specific therapies. Developing novel, successful cancer therapies rely on the use of new techniques such as xenotransplantation and hierarchical CSC models [10] . The possibility of inducing selective differentiation in CSC with the help of LILI holds similar potential for CSC therapy and may contribute to reducing the risk of tumour regeneration where CSC resistance has developed.
